The 10-second takeaway
For the quarter ended March 31 (Q1), BioScrip beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank significantly and GAAP earnings per share dropped to a loss.
Margins contracted across the board.
BioScrip logged revenue of $155.6 million. The two analysts polled by S&P Capital IQ hoped for revenue of $143.5 million on the same basis. GAAP reported sales were 19% higher than the prior-year quarter's $130.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.03. The two earnings estimates compiled by S&P Capital IQ anticipated -$0.01 per share. GAAP EPS were -$0.05 for Q1 compared to $0.05 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 34.4%, 480 basis points worse than the prior-year quarter. Operating margin was 2.9%, 210 basis points worse than the prior-year quarter. Net margin was -1.7%, 390 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $151.8 million. On the bottom line, the average EPS estimate is $0.02.
Next year's average estimate for revenue is $611.8 million. The average EPS estimate is $0.13.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 127 members out of 144 rating the stock outperform, and 17 members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give BioScrip a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on BioScrip is buy, with an average price target of $10.00.
If you're interested in health care stocks like BioScrip, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.
- Add BioScrip to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.